hrp0086p1-p254 | Diabetes P1 | ESPE2016

A Case-Control Search of Environmental (E) Factors for Childhood Type 1 Diabetes (T1D) Using Lifeline Questionnaires in the ISIS-Diab Cohort

Balazard Felix , Le Fur Sophie , Biau Gerard , Valleron Alain-Jacques , Bougneres Pierre

Background: The rapidly increasing T1D incidence in European children suggests the recent emergence or extension of predisposing E factors, or the decrease of protective E factors acting during pregnancy, infancy or early childhood. E research has preferentially focused on specific candidate factors, such as hygiene hypothesis, enteroviruses, alimentation, in cohort or case-control studies. The risk of bias is a major concern in E studies.Objectives: To ...

hrp0086p2-p266 | Diabetes P2 | ESPE2016

Gene-Environment (GxE) Interactions in Childhood Type 1 Diabetes (T1D): A Case-only Geographical Approach in the ISIS-Diab Cohort

Bougneres Pierre , Fur Sophie Le , Valtat Sophie , Lathrop Mark , Valleron Alain-Jacques , ISIS-Diab Network France

Background: T1D concordance in MZ twins being ~40%, non-heritable factors play a major causal role in this autoimmune disease. T1D has recently increased in young European children. Collecting prospective environmental data in a cohort of millions children-years starting soon after birth seems unpracticable. Retrospective case–control studies are an alternative, provided biased controls and recall bias can both be avoided.Objectives: To develop a &#...

hrp0082p3-d1-812 | Growth | ESPE2014

Maternal Inheritance of an Heterozygous Exon 4 IGF1 Gene Mutation (g.65941 G>A) in an IUGR Child with Mild Post Natal Growth Retardation

Houang Muriel , Brioude Frederic , Azzi Salah , Thibaud Nathalie , Perin Laurence , Le Bouc Yves , Netchine Irene

Background: We already described a partial IGF1 primary deficiency due to an exon 4 homozygous missense mutation (g.65941 G>A). A few patients are now described with a heterozygous IGF1 deletion or mutation, questioning about IGF1 haplo insufficiency role in short stature.Results: We describe a boy born from consanguineous parents, with an intra uterine growth restriction (IUGR). Birth weight: 2520 g (−1 SDS) birth length: 46 ...

hrp0084p3-1100 | Pituitary | ESPE2015

Cushing Disease in a Patient with Beckwith–Wiedemann: an Unusual Association

Brioude Frederic , Nicolas Carole , Netchine Irene , Marey Isabelle , Le Bouc Yves , Touraine Philippe

Background: Beckwith–Wiedemann syndrome (BWS) is an overgrowth syndrome with an increased risk of embryonic tumors during early childhood. About 80% of patients with BWS show a molecular defect in the 11p15 imprinted region. Loss of methylation at the imprinting control region 2 (ICR2) is the most frequent defect which leads to a loss of expression of the CDKN1C gene, increasing cell proliferation. These epigenetic defects occur mostly as a mosaic event.<p cl...

hrp0097p1-66 | Fat, Metabolism and Obesity | ESPE2023

Leptin treatment affects adipose progenitor cells physiology

Jasaszwili Mariami , Fuchs Lasse , Richter Sandy , Kirstein Anna , Kiess Wieland , Le Duc Diana , Garten Antje

Introduction: Leptin, an adipokine secreted mainly by adipose tissue, is a regulator of energy balance acting through central mechanisms on the hypothalamus. However, leptin has many functions regulating e.g., immune system and reproduction. Leptin exerts its biological effects through its receptor, the expression of which has been demonstrated in several tissues. There are several leptin receptor isoforms, but activation of only one of them, the long form, re...

hrp0086p1-p6 | Adrenal P1 | ESPE2016

Novel CYP11A1 Mutations in 15 Patients (13 Families) with Variable Clinical Presentations

Goursaud Claire , Roucher-Boulez Florence , Mallet-Motak Delphine , Brauner Raja , Gay Claire Lise , Garcia Ana Mercedes , Lienhardt-Roussie Anne , Jennane Farida , Azar Maryam Razzaghy , Morel Yves

Background: The side chain cleavage enzyme (CYP11A1) catalyzes the conversion of cholesterol to pregnenolone, the first rate-limiting step of steroidogenesis. CYP11A1 mutations are associate with primary adrenal insufficiency (PAI) and, in 46,XY patients, Disorders of Sex Development (DSD). A total of 35 patients (27 families) are reported including 15 intermediate forms with delayed onset of PAI, variable degrees of DSD or normal male phenotype.<p class="abstext"...

hrp0095p1-544 | Pituitary, Neuroendocrinology and Puberty | ESPE2022

Long term effects of continuous subcutaneous infusion of recombinant LH and FSH during infancy on testicular function in congenital hypogonadotropic hypogonadism.

Sophie Lambert Anne , Avril Tristan , Teinturier Cecile , Rothenbuhler Anya , Linglart Agnes , Bouvattier Claire

Context: We previously observed that continuous subcutaneous infusion (CSI) of gonadotropins in infants with congenital hypogonadotropic hypogonadism (CHH) can mimic the hormonal pattern of minipuberty.Objective: Describe the peripubertal outcome in gonadotropins CSI treated patients.Patients: A retrospective study was realised in Bicetre Hospital between 2004 and 2022. Follow-up d...

hrp0095p1-176 | Sex Differentiation, Gonads and Gynaecology, and Sex Endocrinology | ESPE2022

Diagnostic and management practices of girls presenting with polycystic ovary syndrome (PCOS)-like symptoms to a tertiary paediatric endocrine clinic.

Solanas Martín Blanca , R. Howard Sasha , R. Hughes Claire , L. Storr Helen , H. Willemsen Ruben

Background: Polycystic ovary syndrome (PCOS) continues to be a diagnostic challenge in adolescent girls. Symptoms like oligomenorrhea and acne, and polycystic ovarian morphology on ultrasound can be normal variants in adolescents. In addition to diagnostic difficulties, there is lack of randomized controlled trials for PCOS treatments specific to adolescents. Current guidelines for diagnosis and management of PCOS in adolescents have large variations and rely ...

hrp0092fc5.1 | Thyroid | ESPE2019

Randomised Trial of Block and Replace Versus Dose Titration Antithyroid Drug Treatment in Children and Adolescents with Thyrotoxicosis

Wood Claire , Cole Michael , Donaldson Malcolm , Dunger David , Matthews John , Pearce Simon , Cheetham Tim

Background: First line treatment for thyrotoxicosis is thionamide (TA) antithyroid drug therapy. The TA used is usually Carbimazole in the UK. TA can be administered in a relatively large 'blocking' dose that prevents endogenous thyroid hormone synthesis, requiring thyroid hormone replacement (block and replace or BR), or in a smaller dose that renders the patient euthyroid (dose titration or DT). The American Thyroid Association (ATA) recommends DT be...

hrp0086rfc2.7 | Bone &amp; Mineral Metabolism | ESPE2016

Effect of Paternal Loss-of-Function Mutations of GNAS on Growth During the Childhood: A Role for XL

Tran Lea Chantal , Brehin Anne-Claire , Richard Nicolas , Kottler Marie-Laure

Background: Heterozygous GNAS inactivating mutations cause pseudohypoparathyroidism type Ia (PHP-Ia) when maternally inherited and pseudopseudohypoparathyroidism (PPHP)/progressive osseous heteroplasia when paternally inherited. Mutations on the paternal, but not the maternal, GNAS allele are associated with intrauterine growth retardation (IUGR). Moreover, birth weights were lower with paternal GNAS mutations affecting exons 2–13 (including XL and Gαs) than with exo...